tbuckley/cabot-search huggingface dataset:
Pancreatic cancer
Authors: M. M. Murr, M. G. Sarr, A. J. Oishi, J. A. van Heerden
Journal: CA A Cancer Journal for Clinicians (1994)

Pancreatic cancer is a devastating disease for the patient and presents challenging diagnostic and management problems for the physician. A range of serologic and radiologic studies are available for evaluation and staging of this disease. However, invasive studies, including laparotomy, are often necessary to establish the diagnosis and resectability. Despite advances in diagnostic technology that have shortened the interval between onset of symptoms and definitive treatment, no appreciable impact on survival has been demonstrated conclusively. Operative resection offers the only hope for cure, but fewer than 15 percent of patients have resectable disease at the time of diagnosis. Palliative therapy, whether operative or nonoperative, can be performed with low morbidity and provides significant relief of symptoms. Combined-modality treatment with chemotherapy and radiation therapy prolongs survival following curative resection.
Advances in single-cell sequencing: insights from organ transplantation
Authors: Ying Wang, Jian-Ye Wang, Angelika Schnieke, Konrad Fischer
Journal: Military Medical Research (2021)

Abstract Single-cell RNA sequencing (scRNA-seq) is a comprehensive technical tool to analyze intracellular and intercellular interaction data by whole transcriptional profile analysis. Here, we describe the application in biomedical research, focusing on the immune system during organ transplantation and rejection. Unlike conventional transcriptome analysis, this method provides a full map of multiple cell populations in one specific tissue and presents a dynamic and transient unbiased method to explore the progression of allograft dysfunction, starting from the stress response to final graft failure. This promising sequencing technology remarkably improves individualized organ rejection treatment by identifying decisive cellular subgroups and cell-specific interactions.
Abstract 11098: Abnormalities of Left Ventricular Systolic Function in Heart Failure with Preserved Ejection Fraction
Authors: Elisabeth Kraigher-Krainer, Amil M Shah, Michael R Zile, Burkert M Pieske, Adriaan A Voors, Martin P Lefkowitz, Toni L Bransford, Milton Packer, John J McMurray, Scott D Solomon
Journal: Circulation (2012)
Epigenetic strategies to boost CAR T cell therapy
Authors: Behnia Akbari, Navid Ghahri-Saremi, Tahereh Soltantoyeh, Jamshid Hadjati, Saba Ghassemi, Hamid Reza Mirzaei
Journal: Molecular Therapy (2021)

Chimeric antigen receptor (CAR) T cell therapy has led to a paradigm shift in cancer immunotherapy, but still several obstacles limit CAR T cell efficacy in cancers. Advances in high-throughput technologies revealed new insights into the role that epigenetic reprogramming plays in T cells. Mechanistic studies as well as comprehensive epigenome maps revealed an important role for epigenetic remodeling in T cell differentiation. These modifications shape the overall immune response through alterations in T cell phenotype and function. Here, we outline how epigenetic modifications in CAR T cells can overcome barriers limiting CAR T cell effectiveness, particularly in immunosuppressive tumor microenvironments. We also offer our perspective on how selected epigenetic modifications can boost CAR T cells to ultimately improve the efficacy of CAR T cell therapy.
Association of Variants Near the Bradykinin Receptor B2 Gene With Angioedema in Patients Taking ACE Inhibitors
Authors: Jonas Ghouse, Gustav Ahlberg, Laura Andreasen, Karina Banasik, Søren Brunak, Michael Schwinn, Ina Holst Larsen, Oscar Petersen, Erik Sørensen, Henrik Ullum, Eva Rye Rasmussen, Niclas Eriksson, Pär Hallberg, Mia Wadelius, Henning Bundgaard, Morten S. Olesen
Journal: Journal of the American College of Cardiology (2021)
The response to prolonged fasting in hypothalamic serotonin transporter availability is blunted in obesity
Authors: Katy A. van Galen, Jan Booij, Anouk Schrantee, Sofie M. Adriaanse, Unga A. Unmehopa, Eric Fliers, Gary J. Schwartz, Ralph J. DiLeone, Kasper W. ter Horst, Susanne E. la Fleur, Mireille J. Serlie
Journal: Metabolism (2021)

Background and aimsSerotonergic and dopaminergic systems in the brain are essential for homeostatic and reward-associated regulation of food intake and systemic energy metabolism. It is largely unknown how fasting influences these systems or if such effects are altered in humans with obesity. We therefore aimed to evaluate the effects of fasting on hypothalamic/thalamic serotonin transporter (SERT) and striatal dopamine transporter (DAT) availability in lean subjects and subjects with obesity.MethodsIn this randomized controlled cross-over trial, we assessed the effects of 12 vs 24 h of fasting on SERT and DAT availability in the hypothalamus/thalamus and striatum, respectively, using SPECT imaging in 10 lean men and 10 men with obesity.ResultsAs compared with the 12-h fast, a 24-h fast increased hypothalamic SERT availability in lean men, but not in men with obesity. We observed high inter-individual variation in the effects of fasting on thalamic SERT and striatal DAT, with no differences between lean men and those with obesity. In all subjects, fasting-induced increases in circulating free fatty acid (FFA) concentrations were associated with an increase in hypothalamic SERT availability and a decrease in striatal DAT availability. Multiple regression analysis showed that changes in plasma insulin and FFAs together accounted for 44% of the observed variation in striatal DAT availability.ConclusionLean men respond to prolonged fasting by increasing hypothalamic SERT availability, whereas this response is absent in men with obesity. Inter-individual differences in the adaptations of the cerebral serotonergic and dopaminergic systems to fasting may, in part, be explained by changes in peripheral metabolic signals of fasting, including FFAs and insulin.
P-244 Role of preoperative contrast-enhanced computed tomography in staging of gastric cancer in patients undergoing upfront surgery with curative intent
Authors: L. Colney, D. Muduly, M. Imaduddin, S. Ambre, P. Kumar CG, M. Sultania, J. Swain, S. Majumdar, S. Mohakud, S. Patra, M. Kar
Journal: Annals of Oncology (2021)
VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor binding
Authors: Evripidis Lanitis, Paris Kosti, Catherine Ronet, Elisabetta Cribioli, Giorgia Rota, Aodrenn Spill, Patrick Reichenbach, Vincent Zoete, Denarda Dangaj Laniti, George Coukos, Melita Irving
Journal: Journal for ImmunoTherapy of Cancer (2021)

Background The adoptive transfer of chimeric antigen receptor (CAR)-T cells has emerged as a potent immunotherapy against some hematological malignancies but not yet for epithelial-derived solid tumors. One critical issue is the paucity of broadly expressed solid tumor antigens (TAs), and another is the presence of suppressive mechanisms in the tumor microenvironment (TME) that can impair CAR-T cell homing, extravasation and effector functions. TAs expressed by endothelial cells of the tumor vasculature are of clinical interest for CAR therapy because of their genomic stability and accessibility to circulating T cells, as well as their expression across multiple tumor types. In this study, we sought to explore limitations to the efficacy of second-generation (2G) murine CAR-T cells redirected against the vascular endothelial growth factor receptor-2 (VEGFR-2) with the well-characterized single-chain variable fragment DC101. Methods Primary murine T cells were retrovirally transduced to express a 2G anti-VEGFR-2-CAR, and the in vitro binding to VEGFR-2, as well as reactivity against TA-expressing cells, was evaluated in the absence versus presence of exogenous VEGF-A. The CAR-T cells were further tested in vivo for tumor control alone and in combination with anti-VEGF-A antibody. Finally, we performed ex vivo phenotypic analyses of tumor-infiltrating CAR-T cells for the two treatment groups. Results In line with previous reports, we observed poor control of B16 melanoma by the 2G anti-VEGFR-2 CAR-T cells as a monotherapy. We further showed that VEGFR-2 is not downregulated by B16 melanoma tumors post treatment, but that its soluble ligand VEGF-A is upregulated and furthermore competes in vitro with the CAR-T cells for binding to VEGFR-2. This competition resulted in impaired CAR-T cell adhesion and effector function in vitro that could be restored in the presence of anti-VEGF-A antibody. Finally, we demonstrated that coadministration of anti-VEGF-A antibody in vivo promoted CAR-T cell persistence and tumor control and was associated with reduced frequencies of PD-1 + Ki67 - and LAG-3 + Ki67 - CAR-T cells in the TME. Conclusions This study represents the first example of impaired function of a vasculature-targeted CAR by an angiogenic ligand and rationalizes the use of combinatorial therapies that target the tumor vasculature and augment CAR-T cell effector function.
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
Authors: Saad Z Usmani, Alfred L Garfall, Niels W C J van de Donk, Hareth Nahi, Jesus F San-Miguel, Albert Oriol, Laura Rosinol, Ajai Chari, Manisha Bhutani, Lionel Karlin, Lotfi Benboubker, Lixia Pei, Raluca Verona, Suzette Girgis, Tara Stephenson, Yusri Elsayed, Jeffrey Infante, Jenna D Goldberg, Arnob Banerjee, María-Victoria Mateos, Amrita Krishnan
Journal: The Lancet (2021)
Elective nodal radiotherapy in prostate cancer
Authors: Gert De Meerleer, Charlien Berghen, Alberto Briganti, Christof Vulsteke, Julia Murray, Steven Joniau, Anne M Leliveld, Cesare Cozzarini, Karel Decaestecker, Kato Rans, Valerie Fonteyne, Olivier De Hertogh, Alberto Bossi
Journal: The Lancet Oncology (2021)
Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors
Authors: Zhenguang Wang, Na Li, Kaichao Feng, Meixia Chen, Yan Zhang, Yang Liu, Qingming Yang, Jing Nie, Na Tang, Xingying Zhang, Chen Cheng, Lianjun Shen, Jiaping He, Xun Ye, Wei Cao, Haoyi Wang, Weidong Han
Journal: Cellular and Molecular Immunology (2021)

Abstract Programmed cell death protein-1 (PD-1)-mediated immunosuppression has been proposed to contribute to the limited clinical efficacy of chimeric antigen receptor T (CAR-T) cells in solid tumors. We generated PD-1 and T cell receptor (TCR) deficient mesothelin-specific CAR-T (MPTK-CAR-T) cells using CRISPR-Cas9 technology and evaluated them in a dose-escalation study. A total of 15 patients received one or more infusions of MPTK-CAR-T cells without prior lymphodepletion. No dose-limiting toxicity or unexpected adverse events were observed in any of the 15 patients. The best overall response was stable disease (2/15 patients). Circulating MPTK-CAR-T cells peaked at days 7–14 and became undetectable beyond 1 month. TCR-positive CAR-T cells rather than TCR-negative CAR-T cells were predominantly detected in effusion or peripheral blood from three patients after infusion. We further confirmed the reduced persistence of TCR-deficient CAR-T cells in animal models. Our results establish the preliminary feasibility and safety of CRISPR-engineered CAR-T cells with PD-1 disruption and suggest that the natural TCR plays an important role in the persistence of CAR-T cells when treating solid tumors.
Respiratory Care for Patients With Amyotrophic Lateral Sclerosis in the US
Authors: John Hansen-Flaschen
Journal: JAMA Neurology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Abstract 16248: Exercise-Induced Mobilization of Endothelial Progenitor Cells Correlates With Endothelial Dysfunction in Patients With Early Manifestation of Coronary Heart Disease
Authors: Maciej Kazmierski, Wojciech Wojakowski, Aleksandra Michalewska-Wludarczyk, Łukasz Krzych, Michał Tendera
Journal: Circulation (2011)

The aim of this study was to assess the mobilization of endothelial progenitor cells (EPCs) induced by physical exercise and to evaluate the correlation of circulating EPCs with endothelial vasomot...
Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis
Authors: Hagop M. Kantarjian, Timothy P. Hughes, Richard A. Larson, Dong-Wook Kim, Surapol Issaragrisil, Philipp le Coutre, Gabriel Etienne, Carla Boquimpani, Ricardo Pasquini, Richard E. Clark, Viviane Dubruille, Ian W. Flinn, Slawomira Kyrcz-Krzemien, Ewa Medras, Maria Zanichelli, Israel Bendit, Silvia Cacciatore, Ksenia Titorenko, Paola Aimone, Giuseppe Saglio, Andreas Hochhaus
Journal: Leukemia (2021)
Highlights 2013: health through the lens
Authors: Joanna Palmer, Zoë Mullan
Journal: The Lancet Global Health (2013)

“Photography is the only language that can be understood anywhere in the world.”Magnum photographer Bruno Barbey The worn out shoes of a 6-year-old girl in a Tanzanian orphanage. Counterfeit drugs in a back street of Lahore. Prostheses made from recycled material used by landmine victims in Cambodia. Children collecting water from a pump in Haiti. The hands of an elderly woman with severe rheumatoid arthritis in a remote African village. A window in a medical school hostel in Kathmandu, Nepal, repaired with old radiographs and CT scans. These are just some of the images that have featured in The Lancet's annual Highlights photography competition since 2009. The fleeting moment captured in a photograph can be a powerful way to highlight health stories from around the world—from global health to clinical medicine, from the individual person to populations. We invite readers to submit photographs to Highlights 2013 that capture any health issue in a compelling way. This year The Lancet and The Lancet Global Health will run the competition together. Winning photographs will be published in The Lancet's final issue of 2013 and might also be selected for the front cover of The Lancet Global Health. Each entry should be submitted with 300 accompanying words that put the image in context. Submissions should not have been previously published in print or online. If a person or patient is featured then you must obtain and keep written consent from the individual or, where this is not an option, their next of kin. Please complete the patient consent section of the Author statements form while retaining copies of the signed forms. We also encourage you to submit any additional media to support your submission online, such as video or audio features. All photographs—colour or black and white—should be submitted through our online editorial submission system, along with the required text and any supporting material for online publication. Please select Lancet Photograph as the article type. If a digital camera is used please set it to the highest possible quality setting and submit images as JPEG files. If you are using a film camera please submit an 8×11 inch glossy print to The Lancet in the post. The entries will be judged by Lancet editors and there will be a £300 prize for winning entries. The deadline for entries is Nov 12, 2013. So share your photos with The Lancet and The Lancet Global Health: we look forward to seeing them.
Role of anti-HBs in functional cure of HBeAg+ chronic hepatitis B patients infected with HBV genotype A
Authors: Hui Xu, Stephen Locarnini, Darren Wong, Rachel Hammond, Danni Colledge, Sally Soppe, Thao Huynh, Tim Shaw, Alexander J. Thompson, Peter A. Revill, P. Mark Hogarth, Bruce D. Wines, Renae Walsh, Nadia Warner
Journal: Journal of Hepatology (2021)
Screening for Gestational Diabetes
Authors: Karina W. Davidson, Michael J. Barry, Carol M. Mangione, Michael Cabana, Aaron B. Caughey, Esa M. Davis, Katrina E. Donahue, Chyke A. Doubeni, Martha Kubik, Li Li, Gbenga Ogedegbe, Lori Pbert, Michael Silverstein, James Stevermer, Chien-Wen Tseng, John B. Wong
Journal: JAMA (2021)

<h3>Importance</h3> Gestational diabetes is diabetes that develops during pregnancy. Prevalence of gestational diabetes in the US has been estimated at 5.8% to 9.2%, based on traditional diagnostic criteria, although it may be higher if more inclusive criteria are used. Pregnant persons with gestational diabetes are at increased risk for maternal and fetal complications, including preeclampsia, fetal macrosomia (which can cause shoulder dystocia and birth injury), and neonatal hypoglycemia. Gestational diabetes has also been associated with an increased risk of several long-term health outcomes in pregnant persons and intermediate outcomes in their offspring. <h3>Objective</h3> The USPSTF commissioned a systematic review to evaluate the accuracy, benefits, and harms of screening for gestational diabetes and the benefits and harms of treatment for the pregnant person and infant. <h3>Population</h3> Pregnant persons who have not been previously diagnosed with type 1 or type 2 diabetes. <h3>Evidence Assessment</h3> The USPSTF concludes with moderate certainty that there is a moderate net benefit to screening for gestational diabetes at 24 weeks of gestation or after to improve maternal and fetal outcomes. The USPSTF concludes that the evidence on screening for gestational diabetes before 24 weeks of gestation is insufficient, and the balance of benefits and harms of screening cannot be determined. <h3>Recommendation</h3> The USPSTF recommends screening for gestational diabetes in asymptomatic pregnant persons at 24 weeks of gestation or after. (B recommendation) The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for gestational diabetes in asymptomatic pregnant persons before 24 weeks of gestation. (I statement)
Clinical variables associated with psychosis in Alzheimer's disease
Authors: K J Kotrla, R C Chacko, R G Harper, R Doody
Journal: American Journal of Psychiatry (1995)

The authors explored whether personal or family history of major mental illness, negative symptoms, or behavioral measures are associated with positive psychotic symptoms in Alzheimer's disease.Fifty-seven patients with Alzheimer's disease were studied prospectively during interviews with the patients and their primary caregivers.Psychotic patients with Alzheimer's disease did not differ in cognitive functioning from nonpsychotic patients with Alzheimer's disease. No association was found between personal or family history of mental illness and psychosis. Asociality was the only negative symptom associated with psychosis. Psychotic patients had more behavioral disturbances.Positive psychotic symptoms in Alzheimer's disease are not associated with certain aspects of cerebral functioning but are associated with behavioral disturbances.
Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline <i>BRCA</i> Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update
Authors: Nadine M. Tung, Dana Zakalik, Mark R. Somerfield
Journal: Journal of Clinical Oncology (2021)

ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual. The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options.
Turning Purple with Pain
Authors: Thomas W. Fredrick, Manuel B. Braga Neto, Daniel O. Johnsrud, Michael Camilleri, Victor G. Chedid
Journal: New England Journal of Medicine (2021)

A 32-year-old woman presented with a 10-year history of intermittent episodes of severe diffuse abdominal pain, occurring every month or two and usually lasting several days, with no apparent precipitant.
Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial
Authors: Bradley J Monk, Nicoletta Colombo, Amit M Oza, Keiichi Fujiwara, Michael J Birrer, Leslie Randall, Elena V Poddubskaya, Giovanni Scambia, Yaroslav V Shparyk, Myong Cheol Lim, Snehalkumar M Bhoola, Joohyuk Sohn, Kan Yonemori, Ross A Stewart, Xiaoxi Zhang, Julia Perkins Smith, Carlos Linn, Jonathan A Ledermann
Journal: The Lancet Oncology (2021)
The Gold Coast criteria increases the diagnostic sensitivity for amyotrophic lateral sclerosis in a Chinese population
Authors: Dongchao Shen, Xunzhe Yang, Yanying Wang, Di He, Xiaohan Sun, Zhengyi Cai, Jinyue Li, Mingsheng Liu, Liying Cui
Journal: Translational Neurodegeneration (2021)

Abstract Objectives The aim of this study was to assess and compare the diagnostic utility of a new diagnostic criteria for amyotrophic lateral sclerosis (ALS), abbreviated as the ‘Gold Coast Criteria’, with the revised El Escorial (rEEC) and Awaji criteria. Methods Clinical and electrophysiological data of 1185 patients from January 2014 to December 2019 in the Peking Union Medical College Hospital ALS database were reviewed. The sensitivity of the Gold Coast criteria was compared to that of the possible rEEC and Awaji criteria (defined by the proportion of patients categorized as definite, probable, or possible ALS). Results A final diagnosis of ALS was recorded in 1162 patients. The sensitivity of the Gold Coast criteria (96.6%, 95% confidence interval [CI] = 95.3%–97.5%) was greater than that of the rEEC (85.1%, 95%CI = 82.9%–87.1%) and Awaji (85.3%, 95%CI = 83.2%–87.3%). In addition, the sensitivity of the novel criteria maintained robust across subgroups, and the advantage was more prominent in limb-onset ALS patients and those who completed electromyographic tests. In those who did not achieve any of the rEEC diagnostic categories, the sensitivity of Gold Coast criteria was 84.4%. Conclusions The current study demonstrated that the Gold Coast criteria exhibited greater diagnostic sensitivity than the rEEC and Awaji criteria in a Chinese ALS population. The application of the Gold Coast criteria should be considered in clinical practice and future therapeutic trials.
The effect of rate and temperature on patient-reported pain during local anesthesia injection: A single-blinded, randomized, controlled trial
Authors: Amanda Maisel-Campbell, Alexandra Weil, Jake M. Lazaroff, M. Laurin Council, Daniel B. Eisen, Naomi Lawrence, Kira Minkis, Brian R. Chen, Bianca Y. Kang, Sarah A. Ibrahim, Emily Poon, Murad Alam
Journal: Journal of the American Academy of Dermatology (2021)
Time-Course and Influencing Factors of Ventricular Tachy-Arrhythmias after Introduction of Steroid Therapy in Cardiac Sarcoidosis
Authors: Segawa Masato, Fukuda Koji, Nakano Makoto, Kondoh Masateru, Satake Hiroyuki, Hirano Michinori, Shimokawa Hiroaki
Journal: Circulation (2015)